TW200714605A - Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives - Google Patents

Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives

Info

Publication number
TW200714605A
TW200714605A TW095110726A TW95110726A TW200714605A TW 200714605 A TW200714605 A TW 200714605A TW 095110726 A TW095110726 A TW 095110726A TW 95110726 A TW95110726 A TW 95110726A TW 200714605 A TW200714605 A TW 200714605A
Authority
TW
Taiwan
Prior art keywords
thiazolo
amino
substituted
pyrimidine derivatives
novel
Prior art date
Application number
TW095110726A
Other languages
English (en)
Inventor
Gunnar Nordvall
Colin Ray
Tobias Rein
Daniel Sohn
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of TW200714605A publication Critical patent/TW200714605A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
TW095110726A 2005-04-06 2006-03-28 Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives TW200714605A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0500767 2005-04-06

Publications (1)

Publication Number Publication Date
TW200714605A true TW200714605A (en) 2007-04-16

Family

ID=37073739

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095110726A TW200714605A (en) 2005-04-06 2006-03-28 Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives

Country Status (31)

Country Link
US (2) US7947693B2 (zh)
EP (1) EP1869056B1 (zh)
JP (1) JP5165553B2 (zh)
KR (1) KR101335055B1 (zh)
CN (1) CN101193897B (zh)
AR (1) AR055890A1 (zh)
AT (1) ATE487727T1 (zh)
AU (1) AU2006231836B2 (zh)
BR (1) BRPI0609738A2 (zh)
CA (1) CA2604017C (zh)
CY (1) CY1111316T1 (zh)
DE (1) DE602006018124D1 (zh)
DK (1) DK1869056T3 (zh)
ES (1) ES2354450T3 (zh)
HK (1) HK1118556A1 (zh)
HR (1) HRP20110047T1 (zh)
IL (1) IL185912A0 (zh)
MX (1) MX2007012060A (zh)
NO (1) NO20075603L (zh)
NZ (1) NZ561460A (zh)
PL (1) PL1869056T3 (zh)
PT (1) PT1869056E (zh)
RS (1) RS51581B (zh)
RU (1) RU2419623C2 (zh)
SA (1) SA06270072B1 (zh)
SI (1) SI1869056T1 (zh)
TW (1) TW200714605A (zh)
UA (1) UA90707C2 (zh)
UY (1) UY29454A1 (zh)
WO (1) WO2006107258A1 (zh)
ZA (1) ZA200708187B (zh)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4979388B2 (ja) 2004-10-29 2012-07-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 炎症性疾患治療剤
AR053347A1 (es) 2005-04-06 2007-05-02 Astrazeneca Ab Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos
WO2008039139A1 (en) 2006-09-29 2008-04-03 Astrazeneca Ab Novel 5,7-disubstituted [1, 3] thiazolo [4, 5] pyrimidin-2 (3h)-amine derivatives and their use in therapy
TW200820973A (en) 2006-09-29 2008-05-16 Astrazeneca Ab Novel compounds 480
MX2010009624A (es) 2008-03-07 2010-09-28 Acraf Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1 y cx3cr1.
ES2569330T3 (es) 2008-03-07 2016-05-10 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Derivados del 1-bencil-3-hidroximetilindazol y su utilización en el tratamiento de enfermedades basadas en la expresión de MCP-1, CX3CR1
SI2262778T1 (sl) 2008-03-07 2019-12-31 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. 1-benzil-3-hidroksimetilindazolni derivati in njihova uporaba pri zdravljenju bolezni, na osnovi izražanja MCP-1, CXCR1 in P40
TW201100411A (en) 2009-05-21 2011-01-01 Chlorion Pharma Inc Pyrimidines as novel therapeutic agents
JO3437B1 (ar) 2009-10-30 2019-10-20 Esai R & D Man Co Ltd أجسام مضادة محسنة مضادة للفراكتالكين البشري واستخداماتها
EP2648754A4 (en) 2010-12-07 2016-02-24 Philadelphia Health & Educatio METHODS OF INHIBITING THE METASTASIS OF CANCER
JO3082B1 (ar) 2011-09-13 2017-03-15 Eisai R&D Man Co Ltd مشتق بيروليدين-3- يل حمض خليك
US8476301B2 (en) 2011-09-13 2013-07-02 Eisai R&D Management Co., Ltd. Pyrrolidin-3-ylacetic acid derivative
JP5872105B2 (ja) 2013-03-12 2016-03-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピロリジン−３−イル酢酸誘導体の塩およびその結晶
WO2015048281A1 (en) * 2013-09-27 2015-04-02 Nimbus Iris, Inc. Irak inhibitors and uses thereof
WO2016200939A1 (en) * 2015-06-08 2016-12-15 The Johns Hopkins University Radiofluorinated 7-amino-5-thio-thiazolo[4,5-d]pyrimidines for imaging fractalkine receptor (cx3cr1)
WO2018204370A1 (en) 2017-05-02 2018-11-08 Drexel University Cx3cr1 small molecule antagonists, and methods using same
GB201807898D0 (en) 2018-05-15 2018-06-27 Kancera Ab New processes and products with increased chiral purity
GB201811169D0 (en) 2018-07-06 2018-08-29 Kancera Ab New compounds
GB202006849D0 (en) 2020-05-08 2020-06-24 Kancera Ab New use
US20240199558A1 (en) 2022-10-19 2024-06-20 Astrazeneca Ab 2,4,6-trisubstituted 1,3,5-triazines as modulators of cx3cr1

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE543978A (zh) * 1955-01-03
US4698327A (en) * 1985-04-25 1987-10-06 Eli Lilly And Company Novel glycopeptide derivatives
US4643987A (en) * 1985-08-14 1987-02-17 Eli Lilly And Company Modified glycopeptides
US4639433A (en) * 1985-08-14 1987-01-27 Eli Lilly And Company Glycopeptide derivatives
CA2031803C (en) * 1989-12-13 2001-05-29 Ramakrishnan Nagarajan Improvements in or relating to glycopeptide deriveratives
US5202328A (en) * 1991-03-06 1993-04-13 Merck & Co., Inc. Substituted fused pyrimidinones
US5840684A (en) * 1994-01-28 1998-11-24 Eli Lilly And Company Glycopeptide antibiotic derivatives
JP2002510695A (ja) * 1998-04-03 2002-04-09 デュポン ファーマシューティカルズ カンパニー 副腎皮質刺激ホルモン放出因子（ＣＲＦ）拮抗剤としてのチアゾロ［４，５−ｄ］ピリミジンおよびピリジン
WO1999056760A1 (en) 1998-05-01 1999-11-11 Eli Lilly And Company N1-modified glycopeptides
SE9802729D0 (sv) * 1998-08-13 1998-08-13 Astra Pharma Prod Novel Compounds
SE9903544D0 (sv) * 1999-10-01 1999-10-01 Astra Pharma Prod Novel compounds
JP2003522191A (ja) * 2000-02-11 2003-07-22 アストラゼネカ・アクチエボラーグ ケモカイン受容体活性のモジュレーターとしてのピリミジン化合物およびそれらの使用
GB2359081A (en) * 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active thiazolopyrimidines
GB2359551A (en) 2000-02-23 2001-08-29 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
SE0004110L (sv) * 2000-11-10 2002-05-11 Forsheda Ab Tätningsring
SE0101082D0 (sv) * 2001-03-27 2001-03-27 Astrazeneca Ab Novel use
SE0101322D0 (sv) 2001-04-12 2001-04-12 Astrazeneca Ab Novel compounds
GB0221828D0 (en) 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
GB0221829D0 (en) 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
EP2526996B1 (en) * 2002-12-20 2019-09-11 Xeris Pharmaceuticals, Inc. Formulation for intracutaneous injection
BRPI0415050A (pt) 2003-10-07 2006-11-28 Astrazeneca Ab composto, formulação farmacêutica, método para tratar ou reduzir risco de uma doença ou condição humanas, uso de um composto ou de um sal deste farmaceuticamente aceitável, e, processo para a preparação de um composto ou de um sal deste farmaceuticamente aceitável
WO2006064228A2 (en) * 2004-12-17 2006-06-22 Astrazeneca Ab Thiazolopyramidine compounds for the modulation of chemokine receptor activity
AR053347A1 (es) 2005-04-06 2007-05-02 Astrazeneca Ab Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos

Also Published As

Publication number Publication date
UY29454A1 (es) 2006-11-30
JP2008535835A (ja) 2008-09-04
CN101193897A (zh) 2008-06-04
UA90707C2 (en) 2010-05-25
CY1111316T1 (el) 2015-08-05
ZA200708187B (en) 2008-11-26
PT1869056E (pt) 2011-01-13
ATE487727T1 (de) 2010-11-15
US20080214578A1 (en) 2008-09-04
JP5165553B2 (ja) 2013-03-21
AU2006231836B2 (en) 2010-07-15
KR101335055B1 (ko) 2013-12-02
US9440992B2 (en) 2016-09-13
CN101193897B (zh) 2010-12-01
IL185912A0 (en) 2008-01-06
EP1869056B1 (en) 2010-11-10
DE602006018124D1 (de) 2010-12-23
MX2007012060A (es) 2007-12-13
AU2006231836A1 (en) 2006-10-12
CA2604017A1 (en) 2006-10-12
ES2354450T3 (es) 2011-03-15
EP1869056A1 (en) 2007-12-26
RS51581B (en) 2011-08-31
AR055890A1 (es) 2007-09-12
KR20080004483A (ko) 2008-01-09
SI1869056T1 (sl) 2011-02-28
RU2007140551A (ru) 2009-05-20
NZ561460A (en) 2010-12-24
PL1869056T3 (pl) 2011-04-29
US7947693B2 (en) 2011-05-24
HK1118556A1 (en) 2009-02-13
DK1869056T3 (da) 2011-02-07
EP1869056A4 (en) 2010-02-17
NO20075603L (no) 2008-01-04
CA2604017C (en) 2012-03-06
BRPI0609738A2 (pt) 2011-10-18
RU2419623C2 (ru) 2011-05-27
US20110092519A1 (en) 2011-04-21
SA06270072B1 (ar) 2009-02-07
HRP20110047T1 (hr) 2011-03-31
WO2006107258A1 (en) 2006-10-12

Similar Documents

Publication Publication Date Title
TW200714605A (en) Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives
TW200720279A (en) Novel 5,7-disubstituted [1,3]thiazolo[4,5-D]pyrimidin-2(3H)-one derivatives
DK1869049T3 (da) Imidazopyridazinforbindelser
WO2008039139A8 (en) Novel 5,7-disubstituted [1, 3] thiazolo [4, 5] pyrimidin-2 (3h)-amine derivatives and their use in therapy
TW200700068A (en) Phthalazine, aza-and diaza-phthalazine compounds and methods of use
WO2007002667A3 (en) Azaindazole compounds and methods of use
TNSN07164A1 (en) Quinuclidine derivatives and their use as muscarinic m3 receptor antagonists
WO2009050242A3 (de) Heterocyclus-substituierte piperazino-dihydrothienopyrimidine
WO2006038006A3 (en) 5-sulfonyl-1-piperidinyl substituted indole derivatives as 5-ht6 receptor antagonists for the treatment of cns disorders
CY1110711T1 (el) Παραγωγα πυραζολο [3,4-d]αζεπινης ως ανταγωνιστες ισταμινης η3
TW200745130A (en) 2-Heteroaryl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists
NO20080418L (no) Pyrido[2,3-D]pyrimidiriderivater, fremgangsmate for fremstilling derav og terapeutisk anvendelse av samme
WO2008039138A8 (en) Novel 5, 7-disubstituted [1, 3 ] thiazolo [4, 5-d] pyrimidin-2 (3h)-one derivatives and their use in therapy
UY31734A (es) Nuevos derivados 258 5, 7-disustituidos de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona
WO2002076990A8 (en) Thiazolopyrimidine derivatives and use thereof as antagonists of the cx3 cr1 receptor
UA95966C2 (en) 5,7-disubstituted[1,3]thiazolo[4,5]pyrimidin-2(3h)-amine derivatives and their use in therapy
UA95811C2 (en) 5,7-disubstituted [1,3]thiazolo [4,5-d] pyrimidin-2 (3h)-one derivatives and their use in therapy
SE0302666D0 (sv) Novel Compounds
TH81786B (th) อนุพันธ์ของ 5-ซับสทิทิวเทด 7-อะมิโน-[1,3]ไธอะโซโล[4,5-d]พิริมิดีนชนิดใหม่
TH81786A (th) อนุพันธ์ของ 5-ซับสทิทิวเทด 7-อะมิโน-[1,3]ไธอะโซโล[4,5-d]พิริมิดีนชนิดใหม่